Oxidative stress therapy for solid tumors - A proposal

Medical Hypotheses

Volumn 74, Issue 6, 2010, Pages 1052-1054

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CATALASE; DEOXYGLUCOSE; DICHLOROACETIC ACID; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; IRINOTECAN; MENADIONE; PYRUVATE DEHYDROGENASE; RAPAMYCIN; SALICYLIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CELL HYPOXIA; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; HUMAN; HYPOGLYCEMIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATIVE STRESS; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; CATALASE; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; VITAMIN K 3;

RODENTIA;

EID: 77951621559     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.12.029     Document Type: Article

References (58)

1. McCarty M.F., Barroso-Aranda J., Contreras F. A two-phase strategy for treatment of oxidant-dependent cancers. Med Hypotheses 2007, 69(3):489-496.
2. Riordan N.H., Riordan H.D., Meng X., Li Y., Jackson J.A. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 1995, 44(3):207-213.
3. Chen Q., Espey M.G., Krishna M.C., Mitchell J.B., Corpe C.P., Buettner G.R., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005, 102(38):13604-13609.
4. Gonzalez M.J., Miranda-Massari J.R., Mora E.M., Jimenez I.Z., Matos M.I., Riordan H.D., et al. Orthomolecular oncology: a mechanistic view of intravenous ascorbate's chemotherapeutic activity. P R Health Sci J 2002, 21(1):39-41.
5. Padayatty S.J., Levine M. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 2000, 19(4):423-425.
6. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004, 140(7):533-537.
7. Chen Q., Espey M.G., Sun A.Y., Lee J.H., Krishna M.C., Shacter E., et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007, 104(21):8749-8754.
8. Chen Q., Espey M.G., Sun A.Y., Pooput C., Kirk K.L., Krishna M.C., et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008, 105(32):11105-11109.
9. Benade L., Howard T., Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole. Oncology 1969, 23(1):33-43.
10. Bram S., Froussard P., Guichard M., Jasmin C., Augery Y., Sinoussi-Barre F., et al. Vitamin C preferential toxicity for malignant melanoma cells. Nature 1980, 284(5757):629-631.
11. Leung P.Y., Miyashita K., Young M., Tsao C.S. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 1993, 13(2):475-480.
12. Sestili P., Brandi G., Brambilla L., Cattabeni F., Cantoni O. Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther 1996, 277(3):1719-1725.
13. Iwasaka K., Koyama N., Nogaki A., Maruyama S., Tamura A., Takano H., et al. Role of hydrogen peroxide in cytotoxicity induction by ascorbates and other redox compounds. Anticancer Res 1998, 18(6A):4333-4337.
14. Campbell A., Jack T., Cameron E. Reticulum cell sarcoma: two complete 'spontaneous' regressions, in response to high-dose ascorbic acid therapy. A report on subsequent progress. Oncology 1991, 48(6):495-497.
15. Riordan H.D., Casciari J.J., Gonzalez M.J., Riordan N.H., Miranda-Massari J.R., Taylor P., et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005, 24(4):269-276.
16. Padayatty S.J., Riordan H.D., Hewitt S.M., Katz A., Hoffer L.J., Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006, 174(7):937-942.
17. Calderon P.B., Cadrobbi J., Marques C., Hong-Ngoc N., Jamison J.M., Gilloteaux J., et al. Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr Med Chem 2002, 9(24):2271-2285.
18. Verrax J., Cadrobbi J., Delvaux M., Jamison J.M., Gilloteaux J., Summers J.L., et al. The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem 2003, 38(5):451-457.
19. Verrax J., Delvaux M., Beghein N., Taper H., Gallez B., Buc C.P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res 2005, 39(6):649-657.
20. Verrax J., Vanbever S., Stockis J., Taper H., Calderon P.B. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int J Cancer 2007, 120(6):1192-1197.
21. Beck R., Verrax J., Dejeans N., Taper H., Calderon P.B. Menadione reduction by pharmacological doses of ascorbate induces an oxidative stress that kills breast cancer cells. Int J Toxicol 2009, 28(1):33-42.
22. Taper H.S., Jamison J.M., Gilloteaux J., Summers J.L., Calderon P.B. Inhibition of the development of metastases by dietary vitamin C:K3 combination. Life Sci 2004, 75(8):955-967.
23. Verrax J., Stockis J., Tison A., Taper H.S., Calderon P.B. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol 2006, 72(6):671-680.
24. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Ann N Y Acad Sci 2000, 899:349-362.
25. Lin X., Zhang F., Bradbury C.M., Kaushal A., Li L., Spitz D.R., et al. 2-Deoxy-d-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 2003, 63(12):3413-3417.
26. Ahmad I.M., ykin-Burns N., Sim J.E., Walsh S.A., Higashikubo R., Buettner G.R., et al. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 2005, 280(6):4254-4263.
27. Coleman M.C., Asbury C.R., Daniels D., Du J., ykin-Burns N., Smith B.J., et al. 2-Deoxy-d-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008, 44(3):322-331.
28. Aykin-Burns N., Ahmad I.M., Zhu Y., Oberley L.W., Spitz D.R. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 2009, 418(1):29-37.
29. Varma S.D., Devamanoharan P.S., Ali A.H. Prevention of intracellular oxidative stress to lens by pyruvate and its ester. Free Radic Res 1998, 28(2):131-135.
30. Crestanello J.A., Lingle D.M., Millili J., Whitman G.J. Pyruvate improves myocardial tolerance to reperfusion injury by acting as an antioxidant: a chemiluminescence study. Surgery 1998, 124(1):92-99.
31. Wang H.Y., Hochwald S., Port J., Harrison L.E., Ng B., Burt M. Hypoglycemia with glycerol salvage: a role in anti-neoplastic therapy?. Anticancer Res 1995, 15(4):1343-1348.
32. McCarty M.F. Prospects for glycerol-rescued hypoglycemia as a cancer therapy. Med Hypotheses 2001, 56(3):286-289.
33. Nijsten M.W., van Dam G.M. Hypothesis: using the Warburg effect against cancer by reducing glucose and providing lactate. Med Hypotheses 2009, 73(1):48-51.
34. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007, 39(3):231-234.
35. Minchenko A., Leshchinsky I., Opentanova I., Sang N., Srinivas V., Armstead V., et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 2002, 277(8):6183-6187.
36. Robey I.F., Lien A.D., Welsh S.J., Baggett B.K., Gillies R.J. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005, 7(4):324-330.
37. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001, 61(17):6548-6554.
38. Guo S., Miyake M., Liu K.J., Shi H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J Neurochem 2009, 108(5):1309-1321.
39. Williams K.J., Telfer B.A., Airley R.E., Peters H.P., Sheridan M.R., van der Kogel A.J., et al. A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 2002, 21(2):282-290.
40. Cao X., Bloomston M., Zhang T., Frankel W.L., Jia G., Wang B., et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 2008, 14(6):1831-1839.
41. Maher J.C., Wangpaichitr M., Savaraj N., Kurtoglu M., Lampidis T.J. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose. Mol Cancer Ther 2007, 6(2):732-741.
42. McCarty M.F., Barroso-Aranda J., Contreras F. Practical strategies for suppressing hypoxia-inducible factor-1 activity in cancer therapy. Medical Hypotheses 2010, 74(5):789-797.
43. Pencreach E., Guerin E., Nicolet C., Lelong-Rebel I., Voegeli A.C., Oudet P., et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 2009, 15(4):1297-1307.
44. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265(5174):956-959.
45. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396(6706):77-80.
46. Pierce G.L., Lesniewski L.A., Lawson B.R., Beske S.D., Seals D.R. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009, 119(9):1284-1292.
47. Bonello S., Zahringer C., BelAiba R.S., Djordjevic T., Hess J., Michiels C., et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 2007, 27(4):755-761.
48. BelAiba R.S., Bonello S., Zahringer C., Schmidt S., Hess J., Kietzmann T., et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007, 18(12):4691-4697.
49. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453(7196):807-811.
50. Matsumoto K., Imagawa S., Obara N., Suzuki N., Takahashi S., Nagasawa T., et al. 2-Oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia-inducible factor-1alpha and inhibits angiogenesis. J Cell Physiol 2006, 209(2):333-340.
51. Matsumoto K., Obara N., Ema M., Horie M., Naka A., Takahashi S., et al. Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model. Cancer Sci 2009, 100(9):1639-1647.
52. Pan Y., Mansfield K.D., Bertozzi C.C., Rudenko V., Chan D.A., Giaccia A.J., et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 2007, 27(3):912-925.
53. Page E.L., Chan D.A., Giaccia A.J., Levine M., Richard D.E. Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008, 19(1):86-94.
54. Chandel N.S., McClintock D.S., Feliciano C.E., Wood T.M., Melendez J.A., Rodriguez A.M., et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 2000, 275(33):25130-25138.
55. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3(3):177-185.
56. Guzy R.D., Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006, 91(5):807-819.
57. Stacpoole P.W., Henderson G.N., Yan Z., James M.O. Clinical pharmacology and toxicology of dichloroacetate. Environ Health Perspect 1998, 106(Suppl. 4):989-994.
58. Michelakis E.D., Webster L., Mackey J.R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008, 99(7):989-994.